Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Short Interest Update

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the target of a large increase in short interest in September. As of September 15th, there was short interest totaling 177 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average trading volume of 4,062 shares, the short-interest ratio is presently 0.0 days.

Santen Pharmaceutical Stock Performance

SNPHY traded down $0.55 during trading hours on Tuesday, hitting $10.50. 514 shares of the stock were exchanged, compared to its average volume of 9,080. The stock has a 50-day simple moving average of $11.71 and a 200-day simple moving average of $11.73. Santen Pharmaceutical has a 12 month low of $9.22 and a 12 month high of $13.93.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company focused on ophthalmology. The company researches, develops, manufactures and commercializes prescription eye-care medicines and related products for conditions affecting vision and ocular health.

Its portfolio includes treatments for glaucoma and ocular hypertension, dry eye disease, retinal disorders, eye infections and allergies, as well as other ophthalmic conditions. Santen also conducts research in areas such as regenerative medicine and other therapies intended to address unmet needs in eye care.

Founded in Japan in 1890, Santen has expanded beyond its domestic market and serves patients and healthcare professionals across Asia, Europe and other international markets.